Inhibikase Therapeutics reported cash from operations of -$12.44M and free cash flow of -$12.44M for the quarter ended Jun 2026, down 123.2% year over year. This cash flow statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||||||
| Net Income | -4.47M | -5.04M | -4.64M | -4.64M | -4.49M | -4.33M | -4.71M | -6.20M | -4.77M | -4.40M | -4.78M | -5.05M | -5.83M | -12.93M | -14.60M | -10.83M | -12.77M | -13.78M | -17.84M | -21.05M | ||||||
| Share-based CompensationStock Comp. | 0.35M | 0.27M | 0.12M | 0.13M | 0.10M | 0.10M | 0.12M | 0.12M | 0.13M | 0.12M | 0.05M | 0.03M | 0.15M | 7.91M | 2.04M | 4.21M | 4.53M | 4.53M | 5.56M | 5.35M | ||||||
| Gains from Investment SecuritiesGains Investment | 0.18M | 0.03M | ||||||||||||||||||||||||
| Cash from OperationsCash from Ops. | -2.02M | -4.10M | -3.93M | -4.36M | -5.50M | -3.56M | -5.97M | -4.57M | -4.11M | -3.44M | -3.87M | -5.05M | -4.88M | -5.35M | -4.10M | -5.57M | -10.59M | -7.52M | -12.06M | -12.44M | ||||||
| Change in Working Capital | ||||||||||||||||||||||||||
| Change in ReceivablesChange Receivables | -0.37M | -0.11M | -0.06M | -0.04M | 0.01M | 0.14M | 0.02M | 0.02M | -0.08M | |||||||||||||||||
| Change in Account PayablesChange Payables | -0.33M | 0.54M | -0.28M | 0.05M | -0.08M | 0.37M | -0.19M | -0.20M | -0.02M | -0.09M | 0.48M | 0.40M | 0.45M | -1.06M | 0.68M | 0.91M | -1.98M | 0.54M | 0.43M | -0.63M | ||||||
| Change in Accured ExpensesChange Accured Exp. | 1.03M | 0.81M | 0.86M | 0.03M | -1.34M | 0.13M | -0.84M | 0.27M | 0.03M | 0.40M | 0.25M | -0.47M | 0.13M | 0.52M | 0.83M | -0.58M | 0.72M | 0.42M | 0.04M | 5.14M | ||||||
| Investing Activities | ||||||||||||||||||||||||||
| Capital ExpendituresCapex | 0.20M | 0.01M | ||||||||||||||||||||||||
| Cash from Investing ActivitiesCash from Investing | -0.04M | -20.93M | 4.96M | -5.84M | 2.55M | 17.06M | -2.12M | -3.31M | 2.54M | 2.53M | -38.76M | 21.05M | 9.84M | -28.75M | -0.10M | -80.48M | -5.91M | |||||||||
| Financing Activities | ||||||||||||||||||||||||||
| Other financing activitiesOther financing | 0.04M | 41.06M | 0.04M | 0.25M | 0.56M | |||||||||||||||||||||
| Cash from Financing ActivitiesCash from Financing | 0.03M | -0.20M | 8.58M | -0.04M | 70.00 | -0.14M | 0.37M | 3.24M | 0.18M | 99.68M | 0.03M | -0.13M | 108.57M | 2.90M | -0.01M | |||||||||||
| Change in Capital Stock | ||||||||||||||||||||||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 0.21M | 0.05M | 0.02M | 21.33M | 11.63M | |||||||||||||||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | -0.01M | -41.14M | 1.00M | 7.54M | 70.00 | 452.00 | 0.40M | 3.21M | 0.18M | 99.68M | 150.00 | 107.62M | 2.90M | |||||||||||||
| Additional items | ||||||||||||||||||||||||||
| Change in Cash | -1.99M | -4.10M | -4.14M | -4.40M | -26.43M | 1.41M | -3.23M | -2.05M | 12.96M | -5.70M | -6.81M | 0.73M | -2.17M | 55.58M | 16.95M | 4.30M | -39.47M | 100.95M | -89.65M | -18.37M | ||||||
| Free Cash FlowFCF | -2.02M | -4.10M | -3.93M | -4.36M | -5.70M | -3.56M | -5.97M | -4.57M | -4.11M | -3.44M | -3.87M | -5.05M | -4.88M | -5.35M | -4.12M | -5.57M | -10.59M | -7.52M | -12.06M | -12.44M | ||||||
| Net Cash FlowNCF | -1.99M | -4.10M | -4.14M | -4.40M | -26.43M | 1.41M | -3.23M | -2.05M | 12.96M | -5.70M | -6.81M | 0.73M | -2.17M | 55.58M | 16.95M | 4.30M | -39.47M | 100.95M | -89.65M | -18.37M |